Glaxo diabetes drug could come back

The controversial diabetes drug Avandia, currently damaged by a report published in the New England Journal of Medicine and a subsequent Food and Drug Administration warning, could come through the mire unscathed, accord to Glaxo bosses.
The chief executive of GSK, Jean-Pierre Garnier, reportedly commented that the possibility does exist for sales of Avandia to recover lost ground once the company reveals safety data proving the healthcare efficacy of the drug.
The study that gave rise to the storm indicated that Avandia gave diabetic patients a 43 per cent higher risk of heart attack. Glaxo admit that their research shows a 30 per cent increased risk of heart attack, but that the FDA was well aware of this.
Whether or not the company face lawsuits over the drug remains to be seen.